Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florzolotau - APRINOIA Therapeutics

Next Previous
Drug Profile

Florzolotau - APRINOIA Therapeutics

Alternative Names: 1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol; 18F-APN-1607; 18F-PM-PBB3; [18F]-APN-1607([18F]-PM-PBB3); APN-1607; Florzolotau 18F

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator APRINOIA Therapeutics
  • Developer APRINOIA Therapeutics; Chang Gung Memorial Hospital; Nanjing Medical University; National Institute of Radiological Sciences
  • Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Progressive supranuclear palsy
  • No development reported Corticobasal degeneration; Tauopathies

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Tauopathies(Diagnosis) in Japan
  • 11 Sep 2023 APRINOIA Therapeutics plans a pivotal phase III trial for Progressive supranuclear palsy and related tauopathies (Diagnosis) (Parenteral)
  • 28 Aug 2023 APRINOIA Therapeutics plans to file an IND application with the US FDA to initiate a global phase III trial for Progressive supranuclear palsy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top